arrow
C

Christian U. Blank

leiden university medical center
H指数:95
被引数:5.8万

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Five-year survival with neoadjuvant therapy in melanoma: updated pooled analysis from the International Neoadjuvant Melanoma Consortium (INMC)

黑色素瘤新辅助治疗的五年生存率:国际黑色素瘤新辅助治疗协作组(INMC)更新的汇总分析

2026-10-010
OAAI
AI-based histopathology analysis predicts checkpoint inhibitor response in advanced melanoma and identifies patterns associated with response

基于人工智能的病理组织学分析预测晚期黑色素瘤对检查点抑制剂的反应并识别与反应相关的模式

2026-05-250
OAAI
Neoadjuvant ipilimumab plus nivolumab in melanoma: 5-year survival and biomarker analysis from the phase 2 PRADO-trial

黑色素瘤的新辅助治疗ipilimumab联合nivolumab: 来自2期PRADO试验的5年生存率和生物标志物分析

2026-01-280
PRE
Phase I/II Study of AXL-Specific Antibody-Drug Conjugate Enapotamab Vedotin in Patients with Advanced Solid Tumors

晚期实体瘤患者AXL特异性抗体药物偶联物Enapotamab Vedotin的I/II期研究

2025-11-010
OA
International Survey on Evidence for Index Lymph Node Surgery After Neoadjuvant Systemic Therapy for Stage III Melanoma

国际调查:III期黑色素瘤新辅助全身治疗后行哨兵淋巴结手术的证据

2025-10-140
OA
Neoadjuvant ipilimumab and nivolumab in resectable cutaneous squamous cell carcinoma: a randomized phase 2 trial

新辅助伊匹木单抗和纳武利尤单抗在可切除皮肤鳞状细胞癌中的应用:一项随机Ⅱ期临床试验

2025-10-080
OAAI
Clinical, pathological and molecular characteristics of patients with disease recurrence despite pathologic response to neoadjuvant ipilimumab plus nivolumab in stage III melanoma

III期黑色素瘤患者尽管对术前ipiLimumab联合nivolumab治疗表现出病理学反应,但疾病仍复发时的临床、病理及分子特征

2025-09-300
OA
Neoadjuvant PD-1 and LAG-3-targeting bispecific antibody and other immune checkpoint inhibitor combinations in resectable melanoma: the randomized phase 1b/2 Morpheus-Melanoma trial

新辅助PD-1和LAG-3靶向双特异性抗体与其他免疫检查点抑制剂联合治疗可切除黑色素瘤:随机Ib/II期Morpheus-Melanoma试验

2025-09-240
OAAI
Targeted Therapy for Rare BRAF-Mutated Melanoma: Updated Multicenter Analysis and Launch of a Publicly Accessible Online Outcome Database

靶向治疗罕见BRAF突变黑色素瘤:更新后的多中心分析及公共可访问在线结局数据库的建立

2025-08-090
PRE
The association between pretreatment emotional distress and response to tumor-infiltrating lymphocyte therapy in advanced melanoma

治疗前情绪困扰与肿瘤浸润淋巴细胞疗法对晚期黑色素瘤反应之间的关联

2025-07-130
PRE
Rechallenge of ipilimumab and nivolumab in advanced melanoma patients after previous ipilimumab-based therapy

在既往接受过ipilimumab为基础治疗方案的患者中,对晚期黑色素瘤患者进行ipilimumab和nivolumab的重新挑战治疗

2025-04-290
PRE
Adjuvant BRAF/MEK versus anti-PD-1 in BRAF-mutant melanoma: a propensity score matched survival analysis

辅助BRAF/MEK与抗PD-1在BRAF突变黑色素瘤中的倾向性评分匹配生存分析

2025-04-150
PRE
FDG-PET associations with pathological response and survival with neoadjuvant immunotherapy for melanoma

Fdg-pet与黑色素瘤新辅助免疫治疗的病理反应和生存率的关系

2025-03-250
OA
Multiomic profiling of checkpoint inhibitor-treated melanoma: Identifying predictors of response and resistance, and markers of biological discordance (vol 40, pg 88, 2022)

多组学分析:检查点抑制剂治疗的黑色素瘤:识别应答和耐药的预测因子,以及生物学不一致性的标志物(卷40,页88,2022)

2025-02-010
PRE
Cutaneous melanoma: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up

皮肤黑色素瘤:ESMO 临床实践指南(用于诊断、治疗和随访)

2025-01-0111
PRE